Cryopreserved or Fresh Mesenchymal Stromal Cells: Only a Matter of Taste or Key to Unleash the Full Clinical Potential of MSC Therapy?

[1]  G. Lucchini,et al.  Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey , 2016, Haematologica.

[2]  D. Stewart,et al.  Brief Report: Elastin Microfibril Interface 1 and Integrin‐Linked Protein Kinase Are Novel Markers of Islet Regenerative Function in Human Multipotent Mesenchymal Stromal Cells , 2016, Stem cells.

[3]  A. Kirk,et al.  Cryopreserved Mesenchymal Stromal Cells Are Susceptible to T‐Cell Mediated Apoptosis Which Is Partly Rescued by IFNγ Licensing , 2016, Stem cells.

[4]  P. Saas,et al.  Concise Review: Apoptotic Cell‐Based Therapies–Rationale, Preclinical Results and Future Clinical Developments , 2016, Stem cells.

[5]  M. Janowski,et al.  Extracellular Vesicles in Physiology, Pathology, and Therapy of the Immune and Central Nervous System, with Focus on Extracellular Vesicles Derived from Mesenchymal Stem Cells as Therapeutic Tools , 2016, Front. Cell. Neurosci..

[6]  U. Galderisi,et al.  Clinical Trials with Mesenchymal Stem Cells: An Update , 2016, Cell transplantation.

[7]  A. Morelli,et al.  Concise Review: Mechanisms Behind Apoptotic Cell‐Based Therapies Against Transplant Rejection and Graft versus Host Disease , 2016, Stem cells.

[8]  W. Fibbe,et al.  Unraveling mechanisms of mesenchymal stromal cell–mediated immunomodulation through patient monitoring and product characterization , 2016, Annals of the New York Academy of Sciences.

[9]  Michael S. Roberts,et al.  A physiologically based kinetic model for elucidating the in vivo distribution of administered mesenchymal stem cells , 2016, Scientific Reports.

[10]  J. Boltze,et al.  Clumping and Viability of Bone Marrow Derived Mesenchymal Stromal Cells under Different Preparation Procedures: A Flow Cytometry-Based In Vitro Study , 2016, Stem cells international.

[11]  W. V. van IJcken,et al.  Effects of Freeze-Thawing and Intravenous Infusion on Mesenchymal Stromal Cell Gene Expression. , 2016, Stem cells and development.

[12]  F. Chédin,et al.  Comprehensive Proteomic Analysis of Mesenchymal Stem Cell Exosomes Reveals Modulation of Angiogenesis via Nuclear Factor‐KappaB Signaling , 2016, Stem cells.

[13]  J. Krasko,et al.  Identity, proliferation capacity, genomic stability and novel senescence markers of mesenchymal stem cells isolated from low volume of human bone marrow , 2016, Oncotarget.

[14]  C. Aguayo,et al.  Mesenchymal Stem Cell-Derived Extracellular Vesicles Promote Angiogenesis: Potencial Clinical Application , 2016, Front. Physiol..

[15]  S. Ferguson,et al.  An in vitro expansion score for tissue‐engineering applications with human bone marrow‐derived mesenchymal stem cells , 2016, Journal of tissue engineering and regenerative medicine.

[16]  U. Platzbecker,et al.  Mesenchymal Stromal Cells for Treatment of Acute Steroid‐Refractory Graft Versus Host Disease: Clinical Responses and Long‐Term Outcome , 2016, Stem cells.

[17]  Ivan Martin,et al.  International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. , 2016, Cytotherapy.

[18]  B. Giebel,et al.  Mesenchymal stem/stromal cell‐derived extracellular vesicles as a new approach in stem cell therapy , 2016 .

[19]  M. Murad,et al.  Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. , 2016, The Lancet. Haematology.

[20]  R. Henschler,et al.  Biodistribution, migration and homing of systemically applied mesenchymal stem/stromal cells , 2016, Stem Cell Research & Therapy.

[21]  A. Reinisch,et al.  A robust potency assay highlights significant donor variation of human mesenchymal stem/progenitor cell immune modulatory capacity and extended radio-resistance , 2015, Stem Cell Research & Therapy.

[22]  Simon C Watkins,et al.  Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle microRNAs , 2015, Nature Communications.

[23]  Locksley E McGann,et al.  Mesenchymal stromal cells derived from various tissues: Biological, clinical and cryopreservation aspects. , 2015, Cryobiology.

[24]  F. Barry,et al.  Bone Marrow‐Derived Mesenchymal Stem Cells Have Innate Procoagulant Activity and Cause Microvascular Obstruction Following Intracoronary Delivery: Amelioration by Antithrombin Therapy , 2015, Stem cells.

[25]  Xufeng,et al.  Cryopreservation of Human Mesenchymal Stem Cells for Clinical Applications: Current Methods and Challenges , 2015 .

[26]  A. Schmidtchen,et al.  Different Procoagulant Activity of Therapeutic Mesenchymal Stromal Cells Derived from Bone Marrow and Placental Decidua. , 2015, Stem cells and development.

[27]  Thomas Ritter,et al.  Mesenchymal Stem Cell-derived Extracellular Vesicles: Toward Cell-free Therapeutic Applications. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  Rocco,et al.  Enabling Technologies for Cell-Based Clinical Translation Freshly Thawed and Continuously Cultured Human Bone Marrow-Derived Mesenchymal Stromal Cells Comparably Ameliorate Allergic Airways Inflammation in Immunocompetent Mice , 2015 .

[29]  M. Hoogduijn,et al.  Efficacy of immunotherapy with mesenchymal stem cells in man: a systematic review , 2015, Expert review of clinical immunology.

[30]  Jane Ru Choi,et al.  Phenotypic and Functional Characterization of Long-Term Cryopreserved Human Adipose-derived Stem Cells , 2015, Scientific Reports.

[31]  Guido Moll,et al.  Engineering more efficient multipotent mesenchymal stromal (stem) cells for systemic delivery as cellular therapy , 2015 .

[32]  P. Raman,et al.  Genomic and functional comparison of mesenchymal stromal cells prepared using two isolation methods. , 2015, Cytotherapy.

[33]  O. Ringdén,et al.  Immunogenicity of decidual stromal cells in an epidermolysis bullosa patient and in allogeneic hematopoietic stem cell transplantation patients. , 2015, Stem cells and development.

[34]  K. Hoffmann,et al.  Cryopreservation does not alter main characteristics of Good Manufacturing Process-grade human multipotent mesenchymal stromal cells including immunomodulating potential and lack of malignant transformation. , 2015, Cytotherapy.

[35]  Jacques Galipeau,et al.  The challenge of defining mesenchymal stromal cell potency assays and their potential use as release criteria. , 2015, Cytotherapy.

[36]  O. Ringdén,et al.  Treatment of severe chronic graft-versus-host disease with decidual stromal cells and tracing with (111)indium radiolabeling. , 2015, Stem cells and development.

[37]  A. Efimenko,et al.  Autologous Stem Cell Therapy: How Aging and Chronic Diseases Affect Stem and Progenitor Cells , 2015, BioResearch open access.

[38]  J. Baust,et al.  Biobanking: The Future of Cell Preservation Strategies. , 2015, Advances in experimental medicine and biology.

[39]  A. Hubel,et al.  Clinical mesenchymal stromal cell products undergo functional changes in response to freezing. , 2015, Cytotherapy.

[40]  R. Shelton,et al.  The effects of cryopreservation on cells isolated from adipose, bone marrow and dental pulp tissues. , 2014, Cryobiology.

[41]  D. De Fazio,et al.  Frozen adipose-derived mesenchymal stem cells maintain high capability to grow and differentiate. , 2014, Cryobiology.

[42]  O. Korsgren,et al.  Preserved β-Cell Function in Type 1 Diabetes by Mesenchymal Stromal Cells , 2014, Diabetes.

[43]  B. Nilsson,et al.  Cryopreserved Mesenchymal Stromal Cells Display Impaired Immunomodulatory and Therapeutic Properties ? , 2022 .

[44]  Stefanie Dimmeler,et al.  Translational strategies and challenges in regenerative medicine , 2014, Nature Medicine.

[45]  O. Ringdén.  Placenta-derived decidual stromal cells – a novel therapy for graft-versus-host disease, haemorrhages and toxicity after allogeneic haematopoietic stem cell transplantation , 2014 .

[46]  W. Lam,et al.  Actin Cytoskeletal Disruption following Cryopreservation Alters the Biodistribution of Human Mesenchymal Stromal Cells In Vivo , 2014, Stem cell reports.

[47]  G. Stacey,et al.  Putting cells to sleep for future science , 2014, Nature Biotechnology.

[48]  J. Karp,et al.  Mesenchymal stem cells: immune evasive, not immune privileged , 2014, Nature Biotechnology.

[49]  R. Puri,et al.  MSC-based product characterization for clinical trials: an FDA perspective. , 2014, Cell stem cell.

[50]  J. Kurtzberg,et al.  Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[51]  M. Griffin,et al.  Autologous and allogeneic mesenchymal stem cells in organ transplantation: what do we know about their safety and efficacy? , 2014, Current opinion in organ transplantation.

[52]  O. Ringdén,et al.  Stromal cells–are they really useful for GVHD? , 2014, Bone Marrow Transplantation.

[53]  B. Nilsson,et al.  Do ABO Blood Group Antigens Hamper the Therapeutic Efficacy of Mesenchymal Stromal Cells? , 2014, PloS one.

[54]  Yufang Shi,et al.  Immunobiology of mesenchymal stem cells , 2013, Cell Death and Differentiation.

[55]  M. Hoogduijn,et al.  Morphology and size of stem cells from mouse and whale: observational study , 2013, BMJ.

[56]  K. Schmidt-Bleek,et al.  In serum veritas—in serum sanitas? Cell non-autonomous aging compromises differentiation and survival of mesenchymal stromal cells via the oxidative stress pathway , 2013, Cell Death and Disease.

[57]  F. Locatelli,et al.  Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid‐refractory, grade III–IV acute graft‐versus‐host disease , 2013, British journal of haematology.

[58]  H. Klüter,et al.  Functional and differential proteomic analyses to identify platelet derived factors affecting ex vivo expansion of mesenchymal stromal cells , 2013, BMC Cell Biology.

[59]  W. Fibbe,et al.  Mesenchymal stromal cells: sensors and switchers of inflammation. , 2013, Cell stem cell.

[60]  T. Ritter,et al.  Concise review: Adult mesenchymal stromal cell therapy for inflammatory diseases: How well are we joining the dots? , 2013, Stem cells.

[61]  D. Mougiakakos,et al.  Alterations in the Cellular Immune Compartment of Patients Treated with Third‐Party Mesenchymal Stromal Cells Following Allogeneic Hematopoietic Stem Cell Transplantation , 2013, Stem cells.

[62]  W. Weimar,et al.  Mesenchymal stem cells induce an inflammatory response after intravenous infusion. , 2013, Stem cells and development.

[63]  J. Galipeau.  Concerns arising from MSC retrieval from cryostorage and effect on immune suppressive function and pharmaceutical usage in clinical trials , 2013 .

[64]  O. Lindvall,et al.  Regulation of stem cell therapies under attack in Europe: for whom the bell tolls , 2013, The EMBO journal.

[65]  H. Reichenspurner,et al.  Immunological properties of extraembryonic human mesenchymal stromal cells derived from gestational tissue. , 2013, Stem cells and development.

[66]  Preeti Chhabra,et al.  Stem Cell Therapy to Cure Type 1 Diabetes: From Hype to Hope , 2013, Stem cells translational medicine.

[67]  Navrag B. Singh,et al.  Terminally Differentiated CD8+ T Cells Negatively Affect Bone Regeneration in Humans , 2013, Science Translational Medicine.

[68]  E. Horwitz.  Advancing Regenerative Medicine the Translational Way , 2013, Science Translational Medicine.

[69]  N. Fisk,et al.  Mesenchymal stem cells for systemic therapy: shotgun approach or magic bullets? , 2013, BioEssays : news and reviews in molecular, cellular and developmental biology.

[70]  O. Ringdén,et al.  Fetal Membrane Cells for Treatment of Steroid‐Refractory Acute Graft‐Versus‐Host Disease , 2013, Stem cells.

[71]  A. Thiel,et al.  Concerted regulation of CD34 and CD105 accompanies mesenchymal stromal cell derivation from human adventitial stromal cell. , 2013, Stem cells and development.

[72]  R. Henschler,et al.  Cultivation in human serum reduces adipose tissue-derived mesenchymal stromal cell adhesion to laminin and endothelium and reduces capillary entrapment. , 2013, Stem cells and development.

[73]  T. Okano,et al.  Tissue factor triggers procoagulation in transplanted mesenchymal stem cells leading to thromboembolism. , 2013, Biochemical and biophysical research communications.

[74]  L. Bouzas,et al.  Stability of human mesenchymal stem cells during in vitro culture: considerations for cell therapy , 2013, Cell proliferation.

[75]  G. Gross,et al.  Stem Cell-Dependent Therapies: Mesenchymal Stem Cells in Chronic Inflammatory Disorders , 2013 .

[76]  E. Colletti,et al.  Mesenchymal Stem Cells Engineered to Inhibit Complement-Mediated Damage , 2012, PloS one.

[77]  Jacques Galipeau,et al.  The mesenchymal stromal cells dilemma--does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? , 2013, Cytotherapy.

[78]  R. Henschler,et al.  Fate of intravenously injected mesenchymal stem cells and significance for clinical application. , 2013, Advances in biochemical engineering/biotechnology.

[79]  D. Kaufman,et al.  Potential role of mesenchymal stromal cells in pancreatic islet transplantation. , 2013, Transplantation reviews.

[80]  Xu Cao,et al.  The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine , 2013, Nature Medicine.

[81]  S. Dow,et al.  Safety and efficacy of intravenous infusion of allogeneic cryopreserved mesenchymal stem cells for treatment of chronic kidney disease in cats: results of three sequential pilot studies , 2013, Stem Cell Research & Therapy.

[82]  U. Demirci,et al.  Integrating nanoscale technologies with cryogenics: a step towards improved biopreservation. , 2012, Nanomedicine.

[83]  F. Lin,et al.  Mesenchymal stem cells are injured by complement after their contact with serum. , 2012, Blood.

[84]  A. Das,et al.  Comparative cellular and molecular analyses of pooled bone marrow multipotent mesenchymal stromal cells during continuous passaging and after successive cryopreservation , 2012, Journal of cellular biochemistry.

[85]  E. Geissler,et al.  Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion , 2012, Front. Immun..

[86]  C. Hermans,et al.  Bivalirudin in Combination with Heparin to Control Mesenchymal Cell Procoagulant Activity , 2012, PloS one.

[87]  O. Ringdén,et al.  Analysis of Tissues Following Mesenchymal Stromal Cell Therapy in Humans Indicates Limited Long‐Term Engraftment and No Ectopic Tissue Formation , 2012, Stem cells.

[88]  B. Nilsson,et al.  Are Therapeutic Human Mesenchymal Stromal Cells Compatible with Human Blood? , 2012, Stem cells.

[89]  M. Flowers,et al.  Secondary treatment of acute graft-versus-host disease: a critical review. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[90]  O. Lee,et al.  Multiple Intravenous Transplantations of Mesenchymal Stem Cells Effectively Restore Long-Term Blood Glucose Homeostasis by Hepatic Engraftment and β-Cell Differentiation in Streptozocin-Induced Diabetic Mice , 2012, Cell transplantation.

[91]  T. Redmer,et al.  Replicative aging and differentiation potential of human adipose tissue-derived mesenchymal stromal cells expanded in pooled human or fetal bovine serum. , 2012, Cytotherapy.

[92]  D. Mougiakakos,et al.  Multipotent mesenchymal stromal cells and the innate immune system , 2012, Nature Reviews Immunology.

[93]  B. Sander,et al.  Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[94]  C. V. van Blitterswijk,et al.  Therapeutic applications of mesenchymal stromal cells: paracrine effects and potential improvements. , 2012, Tissue engineering. Part B, Reviews.

[95]  N. Kaji,et al.  Monitoring transplanted adipose tissue-derived stem cells combined with heparin in the liver by fluorescence imaging using quantum dots. , 2012, Biomaterials.

[96]  B. Grinblat,et al.  Evaluation of bone marrow-derived mesenchymal stem cells after cryopreservation and hypothermic storage in clinically safe medium. , 2012, Tissue engineering. Part C, Methods.

[97]  R. Romieu-Mourez,et al.  Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing , 2011, Cytotherapy.

[98]  B. Nilsson,et al.  Control of instant blood-mediated inflammatory reaction to improve islets of Langerhans engraftment , 2011, Current opinion in organ transplantation.

[99]  W. Weimar,et al.  Human Mesenchymal Stem Cells Are Susceptible to Lysis by CD8+ T Cells and NK Cells , 2011, Cell transplantation.

[100]  M. Krampera,et al.  Mesenchymal stromal cell ‘licensing’: a multistep process , 2011, Leukemia.

[101]  O. Ringdén,et al.  Pooled MSCs for treatment of severe hemorrhage , 2011, Bone Marrow Transplantation.

[102]  E. Andreu,et al.  Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial , 2011, Haematologica.

[103]  John D Lambris,et al.  Mesenchymal Stromal Cells Engage Complement and Complement Receptor Bearing Innate Effector Cells to Modulate Immune Responses , 2011, PloS one.

[104]  Yu-Hsiang Chang,et al.  Effective Treatment of Severe Steroid-Resistant Acute Graft-Versus-Host Disease With Umbilical Cord-Derived Mesenchymal Stem Cells , 2011, Transplantation.

[105]  H. Northoff,et al.  Expression of blood group genes by mesenchymal stem cells , 2011, British journal of haematology.

[106]  A. Caplan,et al.  Mesenchymal stem cells: mechanisms of inflammation. , 2011, Annual review of pathology.

[107]  P. Bugert,et al.  Altered gene expression in human adipose stem cells cultured with fetal bovine serum compared to human supplements. , 2010, Tissue engineering. Part A.

[108]  Jakub Tolar,et al.  Concise Review: Hitting the Right Spot with Mesenchymal Stromal Cells , 2010, Stem cells.

[109]  J. Karp,et al.  Mesenchymal stem cell therapy: Two steps forward, one step back. , 2010, Trends in Molecular Medicine.

[110]  Carmen Koch,et al.  How to track cellular aging of mesenchymal stromal cells? , 2010, Aging.

[111]  E. Seifried,et al.  Suspension medium influences interaction of mesenchymal stromal cells with endothelium and pulmonary toxicity after transplantation in mice. , 2010, Cytotherapy.

[112]  R. Herrmann,et al.  Prochymal Improves Response Rates In Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-GVHD) Involving The Liver And Gut: Results Of A Randomized, Placebo-Controlled, Multicenter Phase III Trial In GVHD , 2010 .

[113]  John D Lambris,et al.  Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition? , 2010, Trends in immunology.

[114]  H. Ohgushi,et al.  Single intra-arterial injection of mesenchymal stromal cells for treatment of steroid-refractory acute graft-versus-host disease: a pilot study. , 2010, Cytotherapy.

[115]  F. Locatelli,et al.  Mesenchymal Stromal Cells , 2009, Annals of the New York Academy of Sciences.

[116]  D. Strunk,et al.  Human Alternatives to Fetal Bovine Serum for the Expansion of Mesenchymal Stromal Cells from Bone Marrow , 2009, Stem cells.

[117]  S. Savitz,et al.  Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. , 2009, Stem cells and development.

[118]  Jeffrey M Karp,et al.  Mesenchymal stem cell homing: the devil is in the details. , 2009, Cell stem cell.

[119]  S. Totey,et al.  Effect of holding time, temperature and different parenteral solutions on viability and functionality of adult bone marrow‐derived mesenchymal stem cells before transplantation , 2008, Journal of tissue engineering and regenerative medicine.

[120]  A. Uccelli,et al.  Mesenchymal stem cells in health and disease , 2008, Nature Reviews Immunology.

[121]  Yilin Cao,et al.  Evaluation of the viability and osteogenic differentiation of cryopreserved human adipose-derived stem cells. , 2008, Cryobiology.

[122]  S. Dimmeler,et al.  Aging and disease as modifiers of efficacy of cell therapy. , 2008, Circulation research.

[123]  F. Ezquer,et al.  Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[124]  G. Dini,et al.  Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study , 2008, The Lancet.

[125]  E. Jones,et al.  Age-related changes in human bone marrow-derived mesenchymal stem cells: Consequences for cell therapies , 2008, Mechanisms of Ageing and Development.

[126]  R. Zhao,et al.  Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. , 2008, Cell Stem Cell.

[127]  I. Koshima,et al.  Preserved Proliferative Capacity and Multipotency of Human Adipose-Derived Stem Cells after Long-Term Cryopreservation , 2008, Plastic and reconstructive surgery.

[128]  Toshio Miki,et al.  Concise Review: Isolation and Characterization of Cells from Human Term Placenta: Outcome of the First International Workshop on Placenta Derived Stem Cells , 2008, Stem cells.

[129]  E. Gócza,et al.  Mesenchymal Stem Cells Cooperate with Bone Marrow Cells in Therapy of Diabetes , 2008, Stem cells.

[130]  O. Ringdén,et al.  No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients , 2007, Haematologica.

[131]  Q. Han,et al.  Using human adipose tissue-derived mesenchymal stem cells as salvage therapy for hepatic graft-versus-host disease resembling acute hepatitis. , 2007, Transplantation proceedings.

[132]  P. Quesenberry,et al.  Cryopreservation of hematopoietic stem cells , 2007, American journal of hematology.

[133]  H. Klüter,et al.  Human AB Serum and Thrombin‐Activated Platelet‐Rich Plasma Are Suitable Alternatives to Fetal Calf Serum for the Expansion of Mesenchymal Stem Cells from Adipose Tissue , 2007, Stem cells.

[134]  R. Robbins,et al.  Stem cell transplantation: the lung barrier. , 2007, Transplantation proceedings.

[135]  J. Laine,et al.  N‐Glycolylneuraminic Acid Xenoantigen Contamination of Human Embryonic and Mesenchymal Stem Cells Is Substantially Reversible , 2007, Stem cells.

[136]  Meijing Wang,et al.  HIGH PASSAGE NUMBER OF STEM CELLS ADVERSELY AFFECTS STEM CELL ACTIVATION AND MYOCARDIAL PROTECTION , 2006, Shock.

[137]  Darwin J. Prockop,et al.  Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice , 2006, Proceedings of the National Academy of Sciences.

[138]  Hanns-Ulrich Marschall,et al.  Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease , 2006, Transplantation.

[139]  Hermann Eichler,et al.  Comparative Analysis of Mesenchymal Stem Cells from Bone Marrow, Umbilical Cord Blood, or Adipose Tissue , 2006, Stem cells.

[140]  Moustapha Hassan,et al.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells , 2004, The Lancet.

[141]  Shu-Ching Hsu,et al.  Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[142]  A. Flake,et al.  Mesenchymal stem cells: paradoxes of passaging. , 2004, Experimental hematology.

[143]  L. Muul,et al.  Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[144]  A. Caplan,et al.  The Dynamic in vivo Distribution of Bone Marrow-Derived Mesenchymal Stem Cells after Infusion , 2001, Cells Tissues Organs.

[145]  E. Ryan,et al.  Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. , 2000, The New England journal of medicine.

[146]  M. Mastrogiacomo,et al.  Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: Implications for their use in cell therapy. , 2000, Experimental hematology.

[147]  G. Elgue,et al.  Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? , 1999, Diabetes.

[148]  S. Bruder,et al.  Growth kinetics, self‐renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation , 1997, Journal of cellular biochemistry.

[149]  A I Caplan,et al.  The mesengenic process. , 1994, Clinics in plastic surgery.